-
公开(公告)号:US20050256160A1
公开(公告)日:2005-11-17
申请号:US10515653
申请日:2003-05-28
IPC分类号: A61P1/16 , A61P3/10 , A61P5/14 , A61P9/02 , A61P9/10 , A61P9/14 , A61P11/00 , A61P13/00 , A61P13/02 , A61P13/08 , A61P13/10 , A61P13/12 , A61P17/06 , A61P19/10 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/28 , A61P27/02 , A61P27/06 , A61P29/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P43/00 , C07C233/83 , C07C311/46 , C07D209/16 , C07D213/38 , C07D213/40 , C07D217/06 , C07D307/52 , C07D333/20 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/445 , A61K31/195 , A61K31/40 , C07C235/70 , C07D207/30 , C07D211/26
CPC分类号: C07D213/40 , C07C233/83 , C07C311/46 , C07C2602/08 , C07C2602/10 , C07D209/16 , C07D213/38 , C07D217/06 , C07D307/52 , C07D333/20 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12
摘要: A compound of the general formula (I) (wherein the symbols are as defined in the description), or a prodrug or a salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, lower urinary tract symptom (for example, occlusion disease of lower urinary tract), inflammatory disease of lower urinary tract, polyuria), carcinoma association disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease by secretion fault (Sjogren syndrome) or brain association disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy).
摘要翻译: 通式(I)的化合物(其中符号如说明书中所定义)或其前药或其盐。 该化合物参与LPA受体结合和拮抗作用,因此可用于预防和/或治疗泌尿系统疾病(前列腺肥大或神经源性膀胱功能障碍症状,由脊髓肿瘤引起的症状,核疝,椎管狭窄 或糖尿病,下尿路症状(例如下泌尿道闭塞病),下尿路炎性多发尿,多尿症),癌相关疾病(实体瘤,实体瘤转移,血管纤维瘤,骨髓瘤,多发性骨髓瘤,卡波西肉瘤, 炎症/免疫系统疾病(牛皮癣,肾病,肝炎和肺炎症状),分泌性疾病(干燥综合症)或脑关联疾病 (脑梗死,脑中风和脑或周围神经病变)。
-
公开(公告)号:US07285680B2
公开(公告)日:2007-10-23
申请号:US10515653
申请日:2003-05-28
IPC分类号: C07C233/83 , C07C311/46 , C07D209/16 , C07D213/40 , C07D217/06 , C07D307/52
CPC分类号: C07D213/40 , C07C233/83 , C07C311/46 , C07C2602/08 , C07C2602/10 , C07D209/16 , C07D213/38 , C07D217/06 , C07D307/52 , C07D333/20 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12
摘要: A compound of the general formula (I) (wherein the symbols are as defined in the description), or a prodrug or a salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, lower urinary tract symptom (for example, occlusion disease of lower urinary tract), inflammatory disease of lower urinary tract, polyuria), carcinoma association disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease by secretion fault (Sjogren syndrome) or brain association disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy).
摘要翻译: 通式(I)的化合物(其中符号如说明书中所定义)或其前药或其盐。 该化合物参与LPA受体结合和拮抗作用,因此可用于预防和/或治疗泌尿系统疾病(前列腺肥大或神经源性膀胱功能障碍症状,由脊髓肿瘤引起的症状,核疝,椎管狭窄 或糖尿病,下尿路症状(例如下泌尿道闭塞病),下尿路炎性多发尿,多尿症),癌相关疾病(实体瘤,实体瘤转移,血管纤维瘤,骨髓瘤,多发性骨髓瘤,卡波西肉瘤, 炎症/免疫系统疾病(牛皮癣,肾病,肝炎和肺炎症状),分泌性疾病(干燥综合症)或脑关联疾病 (脑梗死,脑中风和脑或周围神经病变)。
-
公开(公告)号:US20080064731A1
公开(公告)日:2008-03-13
申请号:US11851235
申请日:2007-09-06
申请人: Shinji Nakade , Hiromu Habashita , Takuya Seko
发明人: Shinji Nakade , Hiromu Habashita , Takuya Seko
IPC分类号: A61K31/44 , A61K31/195 , A61K31/216 , A61P11/06 , A61P3/04 , A61P9/10 , A61P17/00 , A61K31/415 , A61K31/4184
CPC分类号: C07D213/40 , A61K31/4406 , C07C233/51 , C07C233/66 , C07C233/73 , C07C233/83 , C07C235/48 , C07C235/52 , C07D231/12 , C07D235/12 , C07D261/14
摘要: A remedy and/or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and/or preventing chronic diseases (for example, diseases caused by the progress of chronic asthma, glomerular nephritis, obesity, arteriosclerosis, rheumatoid and atopic diseases) induced and made chronic by tissue cells whose proliferation is accelerated by LPA mediated by EDG-2.
摘要翻译: 含有EDG-2拮抗剂的慢性疾病的补救措施和/或预防措施。 由于与EDA-2的LPA受体的结合,EDG-2拮抗剂可用于治疗和/或预防慢性疾病(例如由慢性哮喘,肾小球肾炎,肥胖症,动脉硬化,类风湿病, 特应性疾病)由EDG-2介导的LPA加速的组织细胞诱导和慢性。
-
公开(公告)号:US20060135577A1
公开(公告)日:2006-06-22
申请号:US10519106
申请日:2003-05-28
申请人: Shinji Nakade , Hiromu Habashita , Takuya Seko
发明人: Shinji Nakade , Hiromu Habashita , Takuya Seko
IPC分类号: A61K31/42 , A61K31/425
CPC分类号: C07D213/40 , A61K31/4406 , C07C233/51 , C07C233/66 , C07C233/73 , C07C233/83 , C07C235/48 , C07C235/52 , C07D231/12 , C07D235/12 , C07D261/14
摘要: A remedy and/or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and/or preventing chronic diseases (for example, diseases caused by the progress of chronic asthma, glomerular nephritis, obesity, arteriosclerosis, rheumatoid and atopic diseases) induced and made chronic by tissue cells whose proliferation is accelerated by LPA mediated by EDG-2.
摘要翻译: 含有EDG-2拮抗剂的慢性疾病的补救措施和/或预防措施。 由于与EDA-2的LPA受体的结合,EDG-2拮抗剂可用于治疗和/或预防慢性疾病(例如由慢性哮喘,肾小球肾炎,肥胖症,动脉硬化,类风湿病, 特应性疾病)由EDG-2介导的LPA加速的组织细胞诱导和慢性。
-
公开(公告)号:US07300917B2
公开(公告)日:2007-11-27
申请号:US10519106
申请日:2003-05-28
申请人: Shinji Nakade , Hiromu Habashita , Takuya Seko
发明人: Shinji Nakade , Hiromu Habashita , Takuya Seko
CPC分类号: C07D213/40 , A61K31/4406 , C07C233/51 , C07C233/66 , C07C233/73 , C07C233/83 , C07C235/48 , C07C235/52 , C07D231/12 , C07D235/12 , C07D261/14
摘要: A remedy and/or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and/or preventing chronic diseases (for example, diseases caused by the progress of chronic asthma, glomerular nephritis, obesity, arteriosclerosis, rheumatoid and atopic diseases) induced and made chronic by tissue cells whose proliferation is accelerated by LPA mediated by EDG-2.
摘要翻译: 含有EDG-2拮抗剂的慢性疾病的补救措施和/或预防措施。 由于与EDA-2的LPA受体的结合,EDG-2拮抗剂可用于治疗和/或预防慢性疾病(例如由慢性哮喘,肾小球肾炎,肥胖症,动脉硬化,类风湿病, 特应性疾病)由EDG-2介导的LPA加速的组织细胞诱导和慢性。
-
公开(公告)号:US07820682B2
公开(公告)日:2010-10-26
申请号:US10530249
申请日:2003-05-28
IPC分类号: A01N43/90 , A01N43/54 , A61K31/519 , A61K31/517 , C07D471/00 , C07D487/00 , C07D401/00 , C07D403/00 , C07D413/00 , C07D417/00 , C07D419/00
CPC分类号: C07D211/96 , C07C217/58 , C07C233/22 , C07C233/51 , C07C233/63 , C07C233/73 , C07C233/87 , C07C235/34 , C07C235/48 , C07C235/52 , C07C2601/08 , C07D207/12 , C07D207/327 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/46 , C07D213/65 , C07D213/89 , C07D217/06 , C07D231/12 , C07D231/14 , C07D235/12 , C07D239/91 , C07D257/04 , C07D277/36 , C07D277/56 , C07D279/08 , C07D307/68 , C07D317/68 , C07D333/70
摘要: A compound of the general formula (I) or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).
摘要翻译: 通式(I)的化合物或其无毒盐。 该化合物与LPA受体结合和拮抗作用有关,可用于预防和/或治疗泌尿系统疾病(前列腺肥大或神经源性膀胱功能障碍症状,脊髓肿瘤引起的症状,核疝,椎管狭窄或 下尿路闭塞性疾病,下尿路炎性疾病,多尿症),癌相关疾病(实体瘤,实体瘤转移,血管纤维瘤,骨髓瘤,多发性骨髓瘤,卡波西肉瘤,乳腺癌和癌性浸润转换),增殖性疾病 (异常血管生成障碍,动脉阻塞和肺纤维化),炎症/免疫系统疾病(牛皮癣,肾病,肝炎和肺炎症状),由分泌功能障碍(干燥综合征)引起的疾病,脑相关疾病(脑梗死,脑中风和 脑或周围神经病)或慢性疾病(慢性哮喘,肾小球性肾炎, 肥胖症,前列腺增生,由动脉硬化过程引起的疾病,风湿病或特应性皮炎)。
-
公开(公告)号:US20060148830A1
公开(公告)日:2006-07-06
申请号:US10530249
申请日:2003-05-28
IPC分类号: A61K31/519 , A61K31/517 , C07D487/02 , C07D403/02
CPC分类号: C07D211/96 , C07C217/58 , C07C233/22 , C07C233/51 , C07C233/63 , C07C233/73 , C07C233/87 , C07C235/34 , C07C235/48 , C07C235/52 , C07C2601/08 , C07D207/12 , C07D207/327 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/46 , C07D213/65 , C07D213/89 , C07D217/06 , C07D231/12 , C07D231/14 , C07D235/12 , C07D239/91 , C07D257/04 , C07D277/36 , C07D277/56 , C07D279/08 , C07D307/68 , C07D317/68 , C07D333/70
摘要: A compound of the general formula (I): (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).
摘要翻译: 通式(I)的化合物或其无毒盐,其中符号如说明书中所定义。 该化合物参与LPA受体结合和拮抗作用,因此可用于预防和/或治疗泌尿系统疾病(前列腺肥大或神经源性膀胱功能障碍症状,由脊髓肿瘤引起的症状,核疝,椎管狭窄 或糖尿病,下尿路闭塞性疾病,下尿路炎症,多尿症),癌相关疾病(实体瘤,实体瘤转移,血管纤维瘤,骨髓瘤,多发性骨髓瘤,卡波西肉瘤,乳腺癌和癌性浸润转换),增殖性 疾病(异常血管生成障碍,动脉阻塞和肺纤维化),炎症/免疫系统疾病(牛皮癣,肾病,肝炎和肺炎症状),由分泌功能障碍(干燥综合征)引起的疾病,脑相关疾病(脑梗塞,脑中风 和脑或周围神经病)或慢性疾病(慢性哮喘,肾小球肾炎) 腹泻,肥胖,前列腺增生,由动脉硬化过程引起的疾病,风湿病或特应性皮炎)。
-
公开(公告)号:US08124645B2
公开(公告)日:2012-02-28
申请号:US12112563
申请日:2008-04-30
IPC分类号: A01N43/38 , A61K31/405 , C07D209/04
CPC分类号: C07D211/96 , C07C217/58 , C07C233/22 , C07C233/51 , C07C233/63 , C07C233/73 , C07C233/87 , C07C235/34 , C07C235/48 , C07C235/52 , C07C2601/08 , C07D207/12 , C07D207/327 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/46 , C07D213/65 , C07D213/89 , C07D217/06 , C07D231/12 , C07D231/14 , C07D235/12 , C07D239/91 , C07D257/04 , C07D277/36 , C07D277/56 , C07D279/08 , C07D307/68 , C07D317/68 , C07D333/70
摘要: A compound of the general formula (I): (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).
摘要翻译: 通式(I)的化合物或其无毒盐,其中符号如说明书中所定义。 该化合物参与LPA受体结合和拮抗作用,因此可用于预防和/或治疗泌尿系统疾病(前列腺肥大或神经源性膀胱功能障碍症状,由脊髓肿瘤引起的症状,核疝,椎管狭窄 或糖尿病,下尿路闭塞病,下尿路炎,多尿症),癌相关疾病(实体肿瘤,实体肿瘤转移,血管纤维瘤,骨髓瘤,多发性骨髓瘤,卡波西肉瘤,乳腺癌和癌性浸润转换),增殖性 疾病(异常血管生成障碍,动脉阻塞和肺纤维化),炎症/免疫系统疾病(牛皮癣,肾病,肝炎和肺炎症状),由分泌功能障碍(干燥综合征)引起的疾病,脑相关疾病(脑梗塞,脑中风 和脑或周围神经病)或慢性疾病(慢性哮喘,肾小球肾炎) 腹泻,肥胖,前列腺增生,由动脉硬化过程引起的疾病,风湿病或特应性皮炎)。
-
公开(公告)号:US20080293764A1
公开(公告)日:2008-11-27
申请号:US12112563
申请日:2008-04-30
IPC分类号: A61K31/47 , C07C63/06 , C07C69/76 , C07D307/02 , C07D215/00 , A61K31/405 , A61P13/02 , A61P35/00 , C07D209/04 , A61K31/192 , A61K31/235 , A61K31/34
CPC分类号: C07D211/96 , C07C217/58 , C07C233/22 , C07C233/51 , C07C233/63 , C07C233/73 , C07C233/87 , C07C235/34 , C07C235/48 , C07C235/52 , C07C2601/08 , C07D207/12 , C07D207/327 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/46 , C07D213/65 , C07D213/89 , C07D217/06 , C07D231/12 , C07D231/14 , C07D235/12 , C07D239/91 , C07D257/04 , C07D277/36 , C07D277/56 , C07D279/08 , C07D307/68 , C07D317/68 , C07D333/70
摘要: A compound of the general formula (I): (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).
摘要翻译: 通式(I)的化合物或其无毒盐,其中符号如说明书中所定义。 该化合物参与LPA受体结合和拮抗作用,因此可用于预防和/或治疗泌尿系统疾病(前列腺肥大或神经源性膀胱功能障碍症状,由脊髓肿瘤引起的症状,核疝,椎管狭窄 或糖尿病,下尿路闭塞性疾病,下尿路炎症,多尿症),癌相关疾病(实体瘤,实体瘤转移,血管纤维瘤,骨髓瘤,多发性骨髓瘤,卡波西肉瘤,乳腺癌和癌性浸润转换),增殖性 疾病(异常血管生成障碍,动脉阻塞和肺纤维化),炎症/免疫系统疾病(牛皮癣,肾病,肝炎和肺炎症状),由分泌功能障碍(干燥综合征)引起的疾病,脑相关疾病(脑梗塞,脑中风 和脑或周围神经病)或慢性疾病(慢性哮喘,肾小球肾炎) 腹泻,肥胖,前列腺增生,由动脉硬化过程引起的疾病,风湿病或特应性皮炎)。
-
公开(公告)号:US20120088782A1
公开(公告)日:2012-04-12
申请号:US13330170
申请日:2011-12-19
IPC分类号: A61K31/24 , A61K31/195 , C07C205/57 , C07D231/12 , A61K31/415 , C07D213/50 , A61K31/4412 , C07D211/60 , A61K31/445 , C07D239/91 , A61K31/517 , A61P13/00 , A61P35/00 , A61P29/00 , A61P37/00 , A61P25/00 , C07C229/38
CPC分类号: C07D211/96 , C07C217/58 , C07C233/22 , C07C233/51 , C07C233/63 , C07C233/73 , C07C233/87 , C07C235/34 , C07C235/48 , C07C235/52 , C07C2601/08 , C07D207/12 , C07D207/327 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/46 , C07D213/65 , C07D213/89 , C07D217/06 , C07D231/12 , C07D231/14 , C07D235/12 , C07D239/91 , C07D257/04 , C07D277/36 , C07D277/56 , C07D279/08 , C07D307/68 , C07D317/68 , C07D333/70
摘要: A compound of the general formula (I): (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).
摘要翻译: 通式(I)的化合物或其无毒盐,其中符号如说明书中所定义。 该化合物参与LPA受体结合和拮抗作用,因此可用于预防和/或治疗泌尿系统疾病(前列腺肥大或神经源性膀胱功能障碍症状,由脊髓肿瘤引起的症状,核疝,椎管狭窄 或糖尿病,下尿路闭塞性疾病,下尿路炎症,多尿症),癌相关疾病(实体瘤,实体肿瘤转移,血管纤维瘤,骨髓瘤,多发性骨髓瘤,卡波西肉瘤,乳腺癌和癌性浸润转换),增殖性 疾病(异常血管生成障碍,动脉阻塞和肺纤维化),炎症/免疫系统疾病(牛皮癣,肾病,肝炎和肺炎症状),由分泌功能障碍(干燥综合征)引起的疾病,脑相关疾病(脑梗塞,脑中风 和脑或周围神经病)或慢性疾病(慢性哮喘,肾小球肾炎) 腹泻,肥胖,前列腺增生,由动脉硬化过程引起的疾病,风湿病或特应性皮炎)。
-
-
-
-
-
-
-
-
-